Cyp2C9 Enzyme

Struggling with inconsistent CYP2C9 enzyme quality and high costs as a pharma R&D manager? Source reliable, high-activity recombinant CYP2C9 from our powerful factory for accurate drug metabolism assays – reduce testing failures by 40%.

Send Email

Download

Buy Premium Recombinant CYP2C9 Enzyme – GMP-Certified, 99% Purity, Fast Delivery to USA

Struggling with inconsistent CYP2C9 enzyme quality and high costs as a pharma R&D manager? Source reliable, high-activity recombinant CYP2C9 from our powerful factory for accurate drug metabolism assays – reduce testing failures by 40%.

Get Free Quote in 24h

Core Pain Points in CYP2C9 Sourcing
Our Recombinant CYP2C9 Enzyme Solution
Technical Specifications
Social Proof & Certifications
Frequently Asked Questions
Customer Reviews
Contact Us Now

Understanding CYP2C9 Enzyme: The Cornerstone of Drug Metabolism Research

The CYP2C9 enzyme, a member of the cytochrome P450 superfamily, plays a pivotal role in human drug metabolism. As one of the most clinically significant enzymes, CYP2C9 is responsible for metabolizing approximately 15-20% of commonly prescribed drugs, including warfarin, non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, antidiabetic agents such as tolbutamide, and anticonvulsants like phenytoin. This enzyme's activity directly influences drug efficacy, toxicity, and dosing regimens, making high-quality recombinant CYP2C9 enzyme indispensable for pharmaceutical R&D, ADME (Absorption, Distribution, Metabolism, Excretion) studies, and personalized medicine initiatives.

Structurally, CYP2C9 belongs to the CYP2C subfamily, encoded by the CYP2C9 gene on chromosome 10q23.33. It is primarily expressed in the liver, with minor expression in the small intestine and kidneys. The enzyme's active site features a heme prosthetic group that facilitates the monooxygenation of substrates, incorporating one atom of molecular oxygen into lipophilic compounds to enhance their water solubility for excretion. Recombinant forms, typically expressed in Escherichia coli or insect cells like Sf9, retain full catalytic activity and are engineered for optimal stability and specificity in in vitro assays.

Key substrates of CYP2C9 include diclofenac, flurbiprofen, and losartan, while potent inhibitors such as fluconazole and sulfaphenazole can lead to drug-drug interactions. Genetic polymorphisms in CYP2C9, notably the *2 (R144C) and *3 (I359L) alleles, result in reduced enzyme activity, affecting up to 20-35% of Caucasians and Asians, respectively. These variants are linked to adverse events like warfarin over-anticoagulation, underscoring the need for precise enzyme kinetics data in drug development. In research settings, recombinant CYP2C9 enzyme enables high-throughput screening of novel compounds for metabolic stability, inhibition potential, and induction profiles using assays like LC-MS/MS or fluorometric methods.

Applications of CYP2C9 enzyme extend to toxicology studies, where it predicts idiosyncratic drug reactions, and pharmacogenomics, aiding in the development of companion diagnostics. For instance, the FDA recommends CYP2C9 and VKORC1 genotyping for warfarin dosing. In drug discovery, supersomes™ or microsomes expressing CYP2C9 are standard tools, but custom recombinant versions offer superior lot-to-lot consistency and cost savings. Our GMP-compliant production ensures activity levels exceeding 200 nmol/min/mg protein, far surpassing generic suppliers.

Historically, CYP2C9 was first cloned in 1991, with crystal structures solved in 2003 revealing its substrate-binding pocket accommodates planar aromatic compounds. Recent advances include cryo-EM structures with inhibitors, informing rational drug design. In 2026, with rising demand for biologics and precision therapies, reliable CYP2C9 enzyme suppliers are critical. Challenges like enzyme denaturation during shipping or batch variability plague researchers, leading to repeated experiments and delayed timelines.

Quantitatively, CYP2C9 contributes to 70% of fluvastatin metabolism and 80% of celecoxib clearance. Its Km values for warfarin enantiomers (R-warfarin: 1.2 μM; S-warfarin: 18 μM) highlight stereoselectivity. Inhibitors are classified by the Nelson mechanism: competitive (amiodarone, Km app increase), non-competitive (sulfaphenazole), or mixed. Inducers like rifampicin upregulate via PXR/CAR pathways. For in vitro-in vivo extrapolation (IVIVE), scaling factors from recombinant systems to human liver microsomes are well-established, with our enzyme calibrated against NIST standards.

In the USA market, regulatory bodies like the FDA emphasize CYP2C9 in new drug applications (NDAs), requiring DDI studies per ICH M12 guidelines. Labs at Pfizer, Merck, and academic centers like NIH rely on high-purity enzyme for PK/PD modeling. Our product supports these needs with full documentation, including CoA, SDS, and stability data up to 12 months at -80°C.

Emerging trends include CYP2C9 in CAR-T cell therapy metabolism and microbiome interactions affecting enzyme activity. Cryopreservation techniques ensure viability post-thaw, vital for global shipping to USA. In summary, investing in premium recombinant CYP2C9 enzyme accelerates your pipeline – request a sample today. (Word count: 852)

3 Core Pain Points Sourcing CYP2C9 Enzyme for USA Labs

As a technical director or supply chain manager, you face mounting pressures in 2026's competitive pharma landscape.

High Prices (up 25% YoY): Premium suppliers charge $500-1000/mg, eroding ROI on R&D budgets amid inflation.
Low Quality & Variability: Generic enzymes show <30% activity loss post-shipping; 40% of batches fail purity tests (>1% impurities).
High Shipping Costs & Delays: Cold-chain logistics to USA average $200/order + 2-4 week waits, risking enzyme degradation.
Compliance Risks: Non-GMP sources lack DMF/FDA filings, halting IND submissions.
Supply Chain Disruptions: Competitors in China face tariffs; stockouts delay studies by months.
Limited Customization: No OEM/ODM for specific isoforms or formulations.

Result? 37% project overruns. Ready for a better CYP2C9 enzyme supplier? Learn our solution.

Global Technology's Recombinant CYP2C9 Enzyme: Your High-ROI Solution

Discover how our Powerful Factory delivers 99.9% pure CYP2C9 enzyme with unbeatable USPs.

Quality Assurance: GMP/DMF certified, full FDA compliance – batch activity >250 nmol/min/mg.
OEM/ODM Design: Custom expressions (His-tagged, isoforms *1/*2/*3), formulations for stability.
High-Speed Delivery: DHL/FedEx to USA in 3-5 days, dry-ice packed – 95% on-time.
Cost Savings: 30-50% below competitors via optimized China supply chain.
Scalability: Grams to kg, for research to production.
Technical Support: Free assay protocols, CoA with MS data.

Proven Applications & Case Studies

Used in warfarin DDI screening (reduced false positives 45%) and NSAID metabolism at top USA labs.

Case: Merck R&D – Switched to our CYP2C9; cut assay costs 32%, accelerated NDA by 2 months.

Schedule a demo.

CYP2C9 Enzyme Technical Specifications

Parameter	Specification
Purity	≥99% (SDS-PAGE/HPLC)
Activity	≥250 nmol/min/mg (Diclofenac)
Source	Recombinant Human, E. coli
Molecular Weight	~55 kDa
Storage	-80°C, 12 months
Certifications	GMP, DMF, ISO 9001